Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response

Alessandra Iurlo, Umberto Gianelli, Alessandro Beghini, Orietta Spinelli, Nicola Orofino, Francesca Lazzaroni, Stefano Cambiaghi, Tamara Intermesoli, Alessandro Rambaldi, Agostino Cortelezzi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Activating mutations of KIT receptor tyrosine kinase have been reported in different neoplasms. The M541L KIT substitution (kitM541l) has been described to be associated with pediatric mastocytosis, to enhance growth rate of the affected cells and to confer higher sensitivity to imatinib therapy. We investigated the presence of kitM541l in five males with chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), all negative for Platelet-derived growth factor-alpha (PDGFR) or PDGFRbeta abnormalities, which responded to imatinib therapy. To assess whether the mutation was constitutive or somatic in nature, we evaluated its presence analyzing either the neoplastic or normal cell population (epidermal cells or CD3-positive T lymphocytes). kitM541l substitution was found in 4 out of 5 patients and in all it was somatic in nature. All patients were treated with low dose imatinib (100 mg daily orally), achieving complete and persistent clinical and hematological remission (median follow-up 74 months). One patient relapsed after 50 months. Our study strongly suggests to search for the kitM541l in patients with CEL, NOS, negative for PDGFRalpha and PDGFRbeta abnormalities, to identify a subgroup of cases who may benefit from low dose imatinib therapy.

Original languageEnglish
Pages (from-to)4665-4670
Number of pages6
JournalOncotarget
Volume5
Issue number13
Publication statusPublished - 2014

Fingerprint

Mutation
Platelet-Derived Growth Factor alpha Receptor
Mastocytosis
Platelet-Derived Growth Factor
Receptor Protein-Tyrosine Kinases
Therapeutics
Pediatrics
T-Lymphocytes
Imatinib Mesylate
Pdgfra-Associated Chronic Eosinophilic Leukemia
Growth
Population
Neoplasms

Keywords

  • CEL-NOS
  • Chronic eosinophilic leukemia
  • Hypereosinophilic syndrome
  • KIT mutation
  • KIT541L

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. / Iurlo, Alessandra; Gianelli, Umberto; Beghini, Alessandro; Spinelli, Orietta; Orofino, Nicola; Lazzaroni, Francesca; Cambiaghi, Stefano; Intermesoli, Tamara; Rambaldi, Alessandro; Cortelezzi, Agostino.

In: Oncotarget, Vol. 5, No. 13, 2014, p. 4665-4670.

Research output: Contribution to journalArticle

Iurlo, Alessandra ; Gianelli, Umberto ; Beghini, Alessandro ; Spinelli, Orietta ; Orofino, Nicola ; Lazzaroni, Francesca ; Cambiaghi, Stefano ; Intermesoli, Tamara ; Rambaldi, Alessandro ; Cortelezzi, Agostino. / Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. In: Oncotarget. 2014 ; Vol. 5, No. 13. pp. 4665-4670.
@article{08c1e77620ac44039c6fcd550cd6d600,
title = "Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response",
abstract = "Activating mutations of KIT receptor tyrosine kinase have been reported in different neoplasms. The M541L KIT substitution (kitM541l) has been described to be associated with pediatric mastocytosis, to enhance growth rate of the affected cells and to confer higher sensitivity to imatinib therapy. We investigated the presence of kitM541l in five males with chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), all negative for Platelet-derived growth factor-alpha (PDGFR) or PDGFRbeta abnormalities, which responded to imatinib therapy. To assess whether the mutation was constitutive or somatic in nature, we evaluated its presence analyzing either the neoplastic or normal cell population (epidermal cells or CD3-positive T lymphocytes). kitM541l substitution was found in 4 out of 5 patients and in all it was somatic in nature. All patients were treated with low dose imatinib (100 mg daily orally), achieving complete and persistent clinical and hematological remission (median follow-up 74 months). One patient relapsed after 50 months. Our study strongly suggests to search for the kitM541l in patients with CEL, NOS, negative for PDGFRalpha and PDGFRbeta abnormalities, to identify a subgroup of cases who may benefit from low dose imatinib therapy.",
keywords = "CEL-NOS, Chronic eosinophilic leukemia, Hypereosinophilic syndrome, KIT mutation, KIT541L",
author = "Alessandra Iurlo and Umberto Gianelli and Alessandro Beghini and Orietta Spinelli and Nicola Orofino and Francesca Lazzaroni and Stefano Cambiaghi and Tamara Intermesoli and Alessandro Rambaldi and Agostino Cortelezzi",
year = "2014",
language = "English",
volume = "5",
pages = "4665--4670",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "13",

}

TY - JOUR

T1 - Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response

AU - Iurlo, Alessandra

AU - Gianelli, Umberto

AU - Beghini, Alessandro

AU - Spinelli, Orietta

AU - Orofino, Nicola

AU - Lazzaroni, Francesca

AU - Cambiaghi, Stefano

AU - Intermesoli, Tamara

AU - Rambaldi, Alessandro

AU - Cortelezzi, Agostino

PY - 2014

Y1 - 2014

N2 - Activating mutations of KIT receptor tyrosine kinase have been reported in different neoplasms. The M541L KIT substitution (kitM541l) has been described to be associated with pediatric mastocytosis, to enhance growth rate of the affected cells and to confer higher sensitivity to imatinib therapy. We investigated the presence of kitM541l in five males with chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), all negative for Platelet-derived growth factor-alpha (PDGFR) or PDGFRbeta abnormalities, which responded to imatinib therapy. To assess whether the mutation was constitutive or somatic in nature, we evaluated its presence analyzing either the neoplastic or normal cell population (epidermal cells or CD3-positive T lymphocytes). kitM541l substitution was found in 4 out of 5 patients and in all it was somatic in nature. All patients were treated with low dose imatinib (100 mg daily orally), achieving complete and persistent clinical and hematological remission (median follow-up 74 months). One patient relapsed after 50 months. Our study strongly suggests to search for the kitM541l in patients with CEL, NOS, negative for PDGFRalpha and PDGFRbeta abnormalities, to identify a subgroup of cases who may benefit from low dose imatinib therapy.

AB - Activating mutations of KIT receptor tyrosine kinase have been reported in different neoplasms. The M541L KIT substitution (kitM541l) has been described to be associated with pediatric mastocytosis, to enhance growth rate of the affected cells and to confer higher sensitivity to imatinib therapy. We investigated the presence of kitM541l in five males with chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), all negative for Platelet-derived growth factor-alpha (PDGFR) or PDGFRbeta abnormalities, which responded to imatinib therapy. To assess whether the mutation was constitutive or somatic in nature, we evaluated its presence analyzing either the neoplastic or normal cell population (epidermal cells or CD3-positive T lymphocytes). kitM541l substitution was found in 4 out of 5 patients and in all it was somatic in nature. All patients were treated with low dose imatinib (100 mg daily orally), achieving complete and persistent clinical and hematological remission (median follow-up 74 months). One patient relapsed after 50 months. Our study strongly suggests to search for the kitM541l in patients with CEL, NOS, negative for PDGFRalpha and PDGFRbeta abnormalities, to identify a subgroup of cases who may benefit from low dose imatinib therapy.

KW - CEL-NOS

KW - Chronic eosinophilic leukemia

KW - Hypereosinophilic syndrome

KW - KIT mutation

KW - KIT541L

UR - http://www.scopus.com/inward/record.url?scp=84905002758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905002758&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 4665

EP - 4670

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -